Skip to main content

Tim Scott

CEO, TEGA Therapeutics

Mr. Scott is co-founder and CEO of TEGA Therapeutics, a glycobiology company focused on lysosomal storage disorders and recombinant heparan sulfates. He previously was co-founder and President of Pharmatek Laboratories, a contract development and manufacturing company (sold to Catalent Pharma Solutions in 2016). Prior to that, he was Senior Vice President at (IPO 2011). Mr. Scott serves on the Board of Avelas, a bioscience company working to create better outcomes for cancer patients with its activatable cell-penetrating peptide technology. He also serves on the board of DTx, a biotechnology company using fatty acid motifs to deliver RNA therapeutics. He previously served on the board of Zacharon Pharmaceuticals (sold to Biomarin 2014). Mr. Scott is immediate past Executive Board Chair of CONNECT, a non-profit organization helping to create and scale innovation companies in San Diego. He also serves as Chair of the Board of Governors, Chair of COVID-19 Task Force, and Chair-elect for BIOCOM, a non-profit organization supporting the needs of bio/pharma companies in California. At UC San Diego, he serves on the Dean’s Advisory Council for the Division of Biological Sciences. In the community, Mr. Scott is chair-elect of the San Diego Blood Bank. He is a trustee for the La Jolla Playhouse, a Tony-award winning regional theatre. And he serves on the board of Outside the Lens, a non-profit providing photography and digital media programs for underserved youth. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.